We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add EYPT Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Duravyu showed encouraging secondary endpoint results in the LUGANO wet AMD study, despite mixed findings.
Top-line LUCIA data are expected in fourth-quarter 2026, potentially supporting an NDA filing in 1H2027.
EYPT completed enrollment in two phase III DME studies, with top-line results expected in Q4'27.
EyePoint (EYPT - Free Report) is a clinical-stage biotechnology company focused on developing treatments for serious retinal diseases that can lead to vision loss.
The company’s growth story largely depends on the success of its lead drug candidate, Duravyu (vorolanib intravitreal insert), which is being developed to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The candidate uses the company’s Durasert E technology to deliver vorolanib, a drug designed to block signals involved in abnormal blood vessel growth and leakage in the retina. The insert is being developed to release the medicine over an extended period, allowing patients to receive treatment less frequently than with conventional eye injections such as Regeneron’s (REGN - Free Report) Eylea (aflibercept), a widely used standard-of-care anti-VEGF treatment.
EyePoint is evaluating Duravyu in two pivotal phase III studies, LUGANO and LUCIA, in wet AMD. The results from the LUGANO study, announced in August 2026, were mixed, as the study failed to meet its primary endpoint in the overall patient population. Despite missing the primary endpoint, Duravyu showed encouraging results on key secondary endpoints. The drug demonstrated the potential to reduce treatment burden, lower the need for additional treatments and maintain favorable safety and disease control.
The company expects to report top-line data from the LUCIA study in the fourth quarter of 2026. Positive data could strengthen the drug’s potential and support EyePoint’s plan to file a new drug application (NDA) in the first half of 2027.
Year to date, shares of EyePoint have plunged 83.5% against the industry’s 0.7% growth.
Image Source: Zacks Investment Research
EYPT’s DME Pipeline Provides Another Potential Growth Driver
Beyond wet AMD, EyePoint is developing Duravyu for DME. EyePoint has completed enrollment in its two phase III studies, COMO and CAPRI. Both studies are evaluating the candidate against REGN’s Eylea, with treatment designed to be repeated every six months. Top-line results are expected in the fourth quarter of 2027. If the drug shows meaningful benefits in these studies, DME could provide a second major indication and expand Duravyu’s commercial opportunity.
Over the past 60 days, estimates for EYPT’s 2026 loss per share have narrowed from $3.59 to $3.51, while 2027 loss per share estimates have improved from $2.63 to $2.36.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , currently sporting a Zacks Rank #1 each.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion, with the average surprise being 240.74%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add EYPT Stock to Your Portfolio Now
Key Takeaways
EyePoint (EYPT - Free Report) is a clinical-stage biotechnology company focused on developing treatments for serious retinal diseases that can lead to vision loss.
The company’s growth story largely depends on the success of its lead drug candidate, Duravyu (vorolanib intravitreal insert), which is being developed to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The candidate uses the company’s Durasert E technology to deliver vorolanib, a drug designed to block signals involved in abnormal blood vessel growth and leakage in the retina. The insert is being developed to release the medicine over an extended period, allowing patients to receive treatment less frequently than with conventional eye injections such as Regeneron’s (REGN - Free Report) Eylea (aflibercept), a widely used standard-of-care anti-VEGF treatment.
EyePoint is evaluating Duravyu in two pivotal phase III studies, LUGANO and LUCIA, in wet AMD. The results from the LUGANO study, announced in August 2026, were mixed, as the study failed to meet its primary endpoint in the overall patient population. Despite missing the primary endpoint, Duravyu showed encouraging results on key secondary endpoints. The drug demonstrated the potential to reduce treatment burden, lower the need for additional treatments and maintain favorable safety and disease control.
The company expects to report top-line data from the LUCIA study in the fourth quarter of 2026. Positive data could strengthen the drug’s potential and support EyePoint’s plan to file a new drug application (NDA) in the first half of 2027.
Year to date, shares of EyePoint have plunged 83.5% against the industry’s 0.7% growth.
Image Source: Zacks Investment Research
EYPT’s DME Pipeline Provides Another Potential Growth Driver
Beyond wet AMD, EyePoint is developing Duravyu for DME. EyePoint has completed enrollment in its two phase III studies, COMO and CAPRI. Both studies are evaluating the candidate against REGN’s Eylea, with treatment designed to be repeated every six months. Top-line results are expected in the fourth quarter of 2027. If the drug shows meaningful benefits in these studies, DME could provide a second major indication and expand Duravyu’s commercial opportunity.
EyePoint, Inc. Price and Consensus
EyePoint, Inc. price-consensus-chart | EyePoint, Inc. Quote
EYPT's Zacks Rank & Estimates
EyePoint currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for EYPT’s 2026 loss per share have narrowed from $3.59 to $3.51, while 2027 loss per share estimates have improved from $2.63 to $2.36.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , currently sporting a Zacks Rank #1 each.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion, with the average surprise being 240.74%.